Avacta Therapeutics (LSE: AVCT) advances FAP-targeting drug conjugate AVA6103 into Phase 1: What’s at stake?

By on    Pharma & Biotech  

Avacta Therapeutics (LSE: AVCT) advances FAP-targeting drug conjugate AVA6103 into Phase 1: What’s at stake?

Avacta Therapeutics (LSE: AVCT) has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration for AVA6103 (also known as FAP-Exd), its second clinical-stage asset developed using the company’s proprietary pre|CISION platform. The IND clearance enables the start of a Phase 1 trial evaluating the safety, tolerability, and dose parameters of […]

Curasight begins Phase 1 trial of uTREAT in glioblastoma, marking shift to clinical-stage radiopharma development

By on    Pharma & Biotech  

Curasight begins Phase 1 trial of uTREAT in glioblastoma, marking shift to clinical-stage radiopharma development

Curasight A/S has dosed the first patient in a Phase 1 clinical trial of uTREAT for glioblastoma, launching the therapeutic half of its uPAR-targeting theranostic platform alongside its companion diagnostic, uTRACE, which is already in Phase 2 for prostate cancer. How curative ambitions shift when a theranostic platform enters human testing in glioblastoma Curasight’s advancement […]